About Zinc finger protein 232
Zinc finger protein 232 (ZNF232) is a protein
from Homo sapiens identified by UniProt accession
Q9UNY5, 444 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Zinc finger protein 232 |
| UniProt accession | Q9UNY5 |
| Gene | ZNF232 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (12)
Diseases linked to this target (Open Targets).
- family history of Alzheimer’s disease · score 0.07
- platelet component distribution width · score 0.07
- mean platelet volume · score 0.05
- lymphocyte count · score 0.05
- late-onset Alzheimers disease · score 0.03
- sum of neutrophil and eosinophil counts · score 0.02
- myeloid white cell count · score 0.02
- body height · score 0.02
- Alzheimer disease · score 0.02
- hepatocellular carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UNY5-F1 | alphafold | PREDICTED | 60.34 | — |
Amino-acid sequence (444 residues)
MEPPGPVRGP LQDSSWYEPS AELVQTRMAV SLTAAETLAL QGTQGQEKMM MMGPKEEEQS CEYETRLPGN HSTSQEIFRQ RFRHLRYQET PGPREALSQL RVLCCEWLRP EKHTKEQILE FLVLEQFLTI LPEELQSWVR GHHPKSGEEA VTVLEDLEKG LEPEPQVPGP AHGPAQEEPW EKKESLGAAQ EALSIQLQPK ETQPFPKSEQ VYLHFLSVVT EDGPEPKDKG SLPQPPITEV ESQVFSEKLA TDTSTFEATS EGTLELQQRN PKAERLRWSP AQEESFRQMV VIHKEIPTGK KDHECSECGK TFIYNSHLVV HQRVHSGEKP YKCSDCGKTF KQSSNLGQHQ RIHTGEKPFE CNECGKAFRW GAHLVQHQRI HSGEKPYECN ECGKAFSQSS YLSQHRRIHS GEKPFICKEC GKAYGWCSEL IRHRRVHARK EPSH
Explore Zinc finger protein 232 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets